Em­ploy­ers cov­er­ing GLP-1s could dou­ble in 2024 as ques­tions over cov­er­age guardrails loom

Em­ploy­ers who of­fer in­sur­ance cov­er­age of the new class of obe­si­ty med­ica­tions could dou­ble next year, ac­cord­ing to a new sur­vey of 500 em­ploy­ers.

Con­duct­ed by the group Ac­co­lade, the sur­vey found 81% of HR de­ci­sion mak­ers in­di­cat­ed they thought there would be em­ploy­ee in­ter­est in cov­er­ing GLP-1s, while just 25% ac­tu­al­ly of­fered cov­er­age. Still, the sur­vey in­di­cat­ed that next year, 43% of em­ploy­er plans could cov­er GLP-1s.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER